2025
Epitalon: normal cells, breast-cancer lines
Telomeres lengthened in both settings. The route, and the identity of the cell, deserve separate attention.
The earlier fibroblast result
The earlier human fetal fibroblast experiment began with cells that lacked telomerase activity. Adding Epithalon induced expression of the catalytic telomerase subunit, hTERT, along with enzyme activity and telomere elongation. It is a compact and arresting result: the cells changed what they expressed, the enzyme became active, and the measured telomeres lengthened.
The appeal is immediate. There is a pleasing sequence to those observations, and a name for the enzyme makes the account feel unusually complete. For me, the neatness becomes misleading when it spreads beyond the experiment. A culture has answered a cellular question; the fate of a person has barely entered the discussion.
Even the original result has a particular cast: human fetal fibroblasts, in vitro. Those words are part of what happened. They prevent an appealing account of a mechanism from quietly becoming a story about any adult who happens to read it.
The later comparison
The later human-cell study included normal IBR.3 fibroblasts and HMEC cells, and the breast-cancer lines 21NT and BT474. Epitalon extended telomere length in normal cells through hTERT upregulation and telomerase activation. In the cancer-cell lines, the extension occurred largely through ALT. Minor ALT activity was also reported in normal cells.
ALT spells out Alternative Lengthening of Telomeres. The distinction already tells us something useful without a tour through every molecular component: telomeres can lengthen while the dominant process behind the change differs between the cell settings. In this experiment, the cancer-cell result cannot be compressed into a second example of the normal-cell mechanism.
My applause falters at that unevenness. The same measured direction—longer telomeres—allows different accounts of how it happened. Calling the whole thing rejuvenation would erase the most interesting feature of the comparison.
Cancer risk in a person
The cancer-cell telomere result leaves me wary of celebrating telomere extension on its own. The experiment supplies no human cancer-risk estimate, and I cannot extract one from a cultured cell line.
For a next experiment, I’d put persistence at the centre: what follows this change in the affected cells, under which conditions, and with what consequences? A finding can be scientifically interesting while leaving a practical decision far out of reach.
There are also animal experiments with reduced tumor counts. They deserve a separate hearing. I prefer the demanding version of this subject, in which a favourable animal result and an uncomfortable cellular result remain available for discussion at the same time.